// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























7277 Abstracts

CAUSE OF CHEST PAIN - SARS-COV-2

Devashish Desai - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Nitroglycerin

NOSOCOMIAL COVID-19 INFECTION IN AN LVAD PATIENT

Samiullah Arshad - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Dexamethasone

ARTERIAL THROMBOSIS IN COVID 19 AND ANTIPHOSPHOLIPID ANTIBODIES

Eiman Elhouderi - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Hydroxychloroquine

ELEVATED INTERLEUKIN-6 LEVELS IN COVID-19-INFECTED PATIENTS ARE ASSOCIATED WITH MAJOR ADVERSE CARDIAC EVENTS AND/OR MORTALITY

Nicholas Nguyen - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

ILS-969

USE OF TOPICAL TRANEXAMIC ACID TO REDUCE BLOOD LOSS IN THORACOLUMBAR SPINE TUBERCULOSIS SURGERY

Ghanshyam Kakadiya - BRITISH ORTHOPAEDIC RESEARCH SOCIETY (BORS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Tranexamic acid

DO WE STILL NEED ANTI-EMBOLISM STOCKINGS? A SYSTEMATIC REVIEW OF THEIR EFFECTIVENESS

Mahmoud Awadallah - BRITISH ORTHOPAEDIC RESEARCH SOCIETY (BORS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Ecothorax for differential diagnosis in elderly patients hospitalized in a healthcare residence during the new coronavirus 2019 pandemic

Simonetta Vernocchi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Heparin

Cerebral venous thrombosis in Covid-19

Amal Saidani - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Happy Hypoxia: A case series

Tarang Kulkarni - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

primaquine

Evaluation of cancer-associated thrombosis risk in patients with lung adenocarcinoma using the COMPASS-CAT risk assessment model

Miltiadis Chrysanthidis - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Inherited thrombophilia in the development of thrombotic conditions in patients with COPD

Elnorahon Abduganieva - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Prevalence and characteristics of venous thromboembolism in severe exacerbation of COPD in a tertiary care hospital in India

Soibam Pahel Meitei - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Venous thromboembolism associated with reduced lung function, dyspnoea and asthma in the general population

Kristin Felicia Nilausen - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Systemic corticosteroids and the risk of venous thromboembolism in COPD patients: A nationwide study of 30.473 outpatients with severe-very severe COPD

Ema Rastoder - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Controversies over the impact of the COVID-19 pandemic on patients with Pulmonary Arterial Hypertension

Nicoleta Sorina Bertici - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Does D-dimer levels on admission predicts venous thromboembolism in patients with COVID-19?

Sabrine Louhaichi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Severe COVID-19 pneumonia: clinical, functional, and imaging outcomes at 4 months

Elise Noel-Savina - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

N/A

Results From A Phase 2a Study Of TMS-007, An SMTP Family Anti-inflammatory Prothrombolytic, On Patients With Acute Ischemic Stroke Up To 12 Hours After Onset

Naoko Nishimura - International Stroke Conference (ISC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

TMS 007

Venous Thromboembolism Among Medicare Beneficiaries Hospitalized With Acute Ischemic Stroke With And Without History Of Covid-19

Xin Tong - International Stroke Conference (ISC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

CM-10

Associations Between Multimorbidity At Stroke/transient Ischaemic Attack Onset With All-cause Mortality Are Not Explained By Blood Biomarkers A Population-based Study

Matthew B Downer - International Stroke Conference (ISC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Fibrinogen (IV)

Copyright © 2026. QuantiNova All rights reserved